|
|
|
Roche strongly outperforms market in first quarter 2009
 |
Datum nieuwsfeit: 16-04-2009 |
|
|
| Scroll de pagina (druk op een toets of muisknop om het scrollen te stoppen) |
Roche
Media Release
Basel, 16 April 2009
Roche strongly outperforms market in first quarter
Genentech transaction completed, integration proceeding rapidly
Roche Group
· Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US
dollars)
· Roche completes transaction to take full ownership of Genentech -- key decisions on organisational
structure and management appointments taken
· Full-year outlook to be updated to include impact of Genentech transaction and communicated with
half-year results
Pharmaceuticals Division
· Sales advance 8% in local currencies and Swiss francs around twice as fast as the global market
driven by key products in the oncology, virology, ophthalmology and inflammation portfolios
· Encouraging response to rollout of RoActemra for rheumatoid arthritis in first EU countries
· MabThera receives EU approval as first-line treatment for chronic lymphocytic leukemia
· FDA advisory panel unanimously supports use of Avastin in patients with previously treated
glioblastoma brain cancer
· Results of phase III trial of Herceptin in HER2-positive inoperable stomach cancer (ToGA) released a
year earlier than expected due to significant overall survival benefit
Diagnostics Division
· Divisional sales grow 8% in local currencies and 3% in Swiss francs, well ahead of the global market
· Professional Diagnostics and Tissue Diagnostics are key growth drivers
· Acquisition of innovatis strengthens Roche Applied Science's cell analysis portfolio
Unless otherwise stated, all growth rates are in local currencies
F. Hoffmann-La Roche Ltd 4070 Basel Corporate Communications Tel. +41 61 688 88 88
Switzerland Roche Group Media Relations Fax +41 61 688 27 75
www.roche.com
1/8
Commenting on the first three months of 2009, Roche CEO Severin Schwan said: `With growth of 8%, the
Roche Group's sales developed very well in the first three months of 2009. Sales in both divisions continued
to grow significantly faster than their respective markets. We are therefore confident that we can achieve our
full-year targets. Following the friendly merger agreement with Genentech and rapid completion of the
transaction, we have made considerable progress with integration activities. We are delighted that Art
Levinson will continue to support us in an active role and that many outstanding individuals from both
Genentech and Roche have committed themselves to driving forward the combined businesses. We will
update our full-year outlook to include the impact of the Genentech transaction when we announce our half-
year results.'
Roche Group
2009 2008 % Change
in local
Sales from January to in US
mCHF mCHF in CHF currencie
March dollars
---
Pharmaceuticals Division 9,216 8,568 8 8 0
Europe/Rest of World* 4,491 4,571 -2 8 -8
United States 3,586 3,326 8 1 1
Japan 1,139 671 70 40 58
Diagnostics Division 2,361 2,287 3 8 -4
Roche Group 11,577 10,855 7 8 -1
* Roche defines Europe/Rest of World as covering Europe and all other countries except Japan and the US
See appendix to this release for details of quarterly sales growth
The Roche Group recorded total sales of 11.6 billion Swiss francs in the first quarter of 2009, an increase of
---
8% in local currencies (7% in Swiss francs; -1% in US dollars) compared with the year-earlier period.
Growth was driven mainly by continued strong sales of key products in the Group's oncology, virology,
ophthalmology and inflammation portfolios, and of Roche Diagnostics' immunoassay systems.
Following the completion of the Genentech transaction, Roche and Genentech have taken important
decisions on organisational structure and key management positions. As already announced, effective 1 May
2009, current Genentech Chairman and CEO Arthur D. Levinson will chair Genentech's new board of
directors and steer the integration of Genentech and Roche on a strategic level. In addition, the Board of
1 Unless otherwise stated, all growth rates are in local currencies
2/8
Roche Holding Ltd will propose Arthur Levinson as a member of the Board of Roche Holding Ltd at the next
Annual General Meeting of Shareholders in 2010. Pascal Soriot, currently Head of Roche's Global Pharma
Commercial Operations, will become CEO of Genentech. Together, Levinson and Soriot will lead the
operational integration team to design the future set-up of the combined company. The integration plans will
be finalised by mid-year, with the goal to have the integration largely completed by the end of 2009.
Roche plans to update its full-year outlook to include the impact of the Genentech transaction when the
Group's half-year results are announced on 23 July.
Pharmaceuticals Division
Solid growth driven by key products -- positive launch of RoActemra in Europe
Sales by the Pharmaceuticals Division in the first three months of 2009 increased 8% in local currencies (8%
in Swiss francs; 0% in US dollars) to 9.2 billion Swiss francs. This is around twice the global market growth
2 3
rate (4.4%). The main sales drivers were Avastin, Herceptin, Tamiflu, MabThera/Rituxan and Lucentis. In
the United States, solid growth of key products compensated for lower seasonal sales of Tamiflu. Sales by
Chugai in Japan increased strongly due to Tamiflu, key anticancer medicines and Actemra. Sales in
Europe/Rest of World were driven by continued demand for key products in Europe and in emerging
markets.
Following approval in the European Union of the novel rheumatoid arthritis (RA) medicine
Actemra/RoActemra (tocilizumab) in January, the response from physicians in the initial launch markets,
including Germany, has been very encouraging. Adoption of Actemra in Japan, where the product was
approved for RA in April 2008, continues to develop well.
In the first quarter of 2009 Avastin (bevacizumab), for advanced colorectal, breast, lung and kidney cancer,
continued to record strong sales growth in all regions, with global sales up 30% to 1.5 billion Swiss francs.
Sales of Herceptin (trastuzumab), for HER2-positive breast cancer, increased 11% to 1.3 billion Swiss francs,
driven by continued uptake in early breast cancer in Japan and increasing market penetration in Eastern
Europe and emerging markets. Overall sales (oncology and autoimmune diseases) of MabThera/Rituxan
(rituximab), for non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid
arthritis (RA), rose 6% to 1.5 billion Swiss francs. While uptake continues to increase in the first-line NHL
2 Pharmaceutical market growth according to IMS (to end December 2008)
3 Sales of the Roche Group's 20 leading pharmaceutical products are presented in the appendix to this release
3/8
setting, high adoption rates for this indication have already been achieved in most markets. The European
rollout of MabThera for CLL and further uptake in the NHL maintenance setting and in RA are expected to
contribute additional sales growth.
Global sales of Tamiflu (oseltamivir), for influenza, rose 38% overall to 401 million Swiss francs in the first
quarter. Growth was driven by sales to governments and corporations for pandemic stockpiling, including
significant new orders in Japan and the United Kingdom, where the governments have announced plans to
double the size of their existing stockpiles of antiviral medicines. This more than compensated for lower
seasonal sales, particularly in the United States, where flu outbreaks were less severe than in the 2007/2008
season.
Sales in the US of Lucentis (ranibizumab), for wet age-related macular degeneration, increased 21% to 279
million Swiss francs. Growth is being driven primarily by an increase in the number of injections per patient
in the first and second year of treatment and an improving market environment compared with the first
quarter last year.
Combined sales of Roche's NeoRecormon and Chugai's Epogin (epoetin beta), for anemia, declined 13% to
378 million Swiss francs in a highly competitive market. While the market share of NeoRecormon remained
virtually stable, sales were affected by continued price pressure.
At the beginning of April, Roche and Genentech announced a phased voluntary withdrawal of the psoriasis
drug Raptiva (efalizumab) from the US market.
Major product development milestones
In February Roche received EU approval for MabThera in combination with chemotherapy for previously
untreated chronic lymphocytic leukemia (CLL), the most common form of adult leukemia. Roche filed an
application in January for approval of MabThera for relapsed or refractory CLL, based on results of the
REACH trial.
In March a US Food and Drug Administration (FDA) advisory panel issued a unanimous recommendation
supporting the use of Avastin in patients with previously treated (relapsed) glioblastoma, the most aggressive
form of brain tumour. A decision by the FDA on accelerated approval of this new indication is expected in
May.
4/8
Four-year follow-up data presented in March from an ongoing clinical trial (HERA) showed that women
with HER2-positive early breast cancer continue to benefit from Herceptin several years after the end of
treatment. Also in March, Roche announced positive results from an international phase III trial (ToGA) that
showed that adding Herceptin to standard chemotherapy significantly prolongs the lives of patients with
advanced and inoperable HER2-positive stomach cancer. Because of the significant overall survival benefit,
the results were released approximately one year earlier than anticipated. Full data will be presented at a
forthcoming medical conference.
In March Roche and OSI Pharmaceuticals submitted applications to the European Medicines Agency
(EMEA) and the FDA, respectively, for approval of Tarceva (erlotinib) as maintenance therapy in patients
with advanced non-small cell lung cancer (NSCLC) whose disease has not progressed following first-line
chemotherapy. Both filings are based on data from the phase III SATURN trial. Interim results from another
phase III study (ATLAS) were released in February. The data showed that maintenance treatment with
Tarceva and Avastin in combination extends progression-free survival in patients with advanced NSCLC. The
study was stopped early because of the significance of the interim data, which Roche plans to discuss with the
regulatory authorities to determine next steps.
Research and development update
As of 31 March 2009, the Pharmaceuticals Division's research and development pipeline (phase I to
III/registration) included 59 new molecular entities and 59 additional indications. During the first quarter
one project entered phase I, four projects entered phase II and two entered phase III development. Portfolio
prioritisations led to the discontinuation of three phase I and two phase II projects.
The first phase III trial (EMILIA) investigating the novel antibodydrug conjugate trastuzumab-DM1 in the
second-line treatment of patients with HER2-positive metastatic breast cancer commenced in February.
Phase III development of dalcetrapib (CETP inhibitor), for dyslipidemia, and taspoglutide (GLP-1 analogue),
for type 2 diabetes, is progressing according to plan. Due to the progress made with dalcetrapib, development
of a back-up CETP inhibitor, R7232, has been stopped. Initial data from the taspoglutide trial are expected by
the end of the year. Roche is focusing development activities in type 2 diabetes on molecules that, in addition
to achieving glucose reduction, have the potential to lower cardiovascular risk. Accordingly, Roche has
moved R7201, a novel SGLT-2 inhibitor licensed from Chugai, into phase II testing. Development of early-
stage compounds that would only lower glucose levels, including all glucokinase activators, has been
discontinued.
5/8
In the first quarter of 2009 Roche announced new licensing agreements with Plexxikon for PLX5568 (R7376),
a novel kinase inhibitor for polycystic kidney disease, and with Evotec for phase II development of EVT 101
for treatment-resistant depression. The acquisition of US-based Memory Pharmaceuticals was completed in
January.
Diagnostics Division
Continued above-market sales growth with nine major product launches in Europe
Roche's Diagnostics Division, the world's leading supplier of in vitro diagnostics (IVDs), recorded first-
quarter sales of 2.4 billion Swiss francs, an increase of 8% in local currencies (3% in Swiss francs, -4% in US
---
dollars). This was well above the estimated 5% growth of the IVD market. All five business areas increased
their sales in local currencies, with Professional Diagnostics and Tissue Diagnostics the biggest contributors
to growth. The division launched nine major new IVDs in Europe as well as important additions to its DNA
sequencing and cell analysis portfolios.
Roche Professional Diagnostics' sales rose 8% to 1,086 million Swiss francs. The immunoassay business
gained further market share on sales growth of 18%. New placements of cobas 6000 analysers and recent
additions to the immunoassay menu like the Elecsys anti-CCP assay (diagnosis of rheumatoid arthritis) were
key growth drivers. Sales of decentralised solutions rose 4%, led by strong demand for portable testing
systems like the CoaguChek coagulation monitors. In the EU and other markets recognising CE Mark
certification the business area launched a highly sensitive test for cardiac troponin T (diagnosis of heart
attack), a test for the inflammation marker interleukin 6 (as an aid in managing critically ill patients) and
assays for the markers PlGF and sFlt-1, which together provide the first and only IVD for preeclampsia, a
potentially life-threatening complication of pregnancy.
Roche Diabetes Care's combined sales of blood glucose (BG) monitoring and insulin delivery products rose
4% to 679 million Swiss francs. Sales of Roche's top-selling Accu-Chek Aviva BG system increased nearly
30%. Roche Diabetes Care has begun rolling out three major new BG monitoring systems in Europe: Accu-
Chek Mobile (featuring strip-free technology), Accu-Chek Aviva Nano (for young, frequent testers) and
Accu-Chek Active (for emerging markets). In addition, Accu-Chek Combo, Europe's first interactive diabetes
management system combining an insulin pump and a BG meter/remote control, was launched in its first
4 Diagnostics market growth according to company estimates and various industry reports.
6/8
markets.
Roche Molecular Diagnostics' sales rose 7% to 294 million Swiss francs. Automated real-time PCR platforms
remained a growth driver. Sales of blood screening products increased 12%. Uptake of automated HIV and
hepatitis B viral load tests remained strong, contributing to overall virology sales growth of 5%. The business
area's LightCycler MRSA Advanced Test for improved screening for methicillin-resistant Staphylococcus
aureus was CE Mark certified in March and commercially launched in Europe in April. In oncology, the
TheraScreen K-RAS Test, which Roche began distributing in December 2008, is now validated for use on the
LightCycler 480 II instrument, expanding platform options for laboratories.
Roche Applied Science's sales rose 6% to 196 million Swiss francs. Sales of DNA sequencing products and
microarrays both showed high double-digit growth. Systems for sample preparation and real-time
quantitative PCR analysis posted 4% growth despite price erosion in the market. In early April Roche
complemented its existing cell analysis portfolio for research by acquiring innovatis AG, a leader in
automated cell analysis solutions for biomanufacturing. Important launches included a new version of the
xCELLigence cell analyser and new Titanium DNA sequencing reagent kits.
Roche Tissue Diagnostics' first-quarter sales totalled 106 million Swiss francs, up 55% compared with two
months' sales in 2008 due to the timing of the Ventana acquisition. On a comparable basis, sales rose 14%,
again outpacing the market. Advanced tissue staining (immunohistochemistry and in situ hybridisation)
continued to be the main growth driver, delivering a robust double-digit sales increase. Last year's upgrades
to the Symphony slide staining system contributed to double-digit growth in the high-volume primary
staining market. In March the business area launched the INFORM EGFR DNA Probe in Europe for clinical
use in oncology.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined
strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly
differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's
personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D.
7/8
The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of
the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:
www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Additional information
- Media release including a full set of tables: www.roche.com/med-cor-2009-04-16
- Roche Pharma pipeline: www.roche.com/pipeline.htm
- Roche Diagnostics pipeline: www.roche.com/diagnostics_portfolio
- Roche Finance Info System: rofis.roche.com/dynasight/rofis.html
Next events
- Half-year results 2009: 23 July 2009 (tentative date)
Roche Group Media Relations
Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com
- Daniel Piller (Head)
- Alexander Klauser
- Valeria Passoni
- Martina Rupp
- Claudia Schmitt
Disclaimer: Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as
`believes', `expects', `anticipates', `projects', `intends', `should', `seeks', `estimates', `future' or similar expressions or by discussion of,
among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from
those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of
competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory
approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5)
uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without
limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6)
increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for
intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news
coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that
Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published
earnings or earnings per share of Roche.
8/8
1. Sales January to March 2009 and 2008
2009 2008 % change
In local
January March CHF m CHF m In CHF
currencies
Pharmaceuticals Division 9,216 8,568 +8 +8
Europe/Rest of World 4,491 4,571 -2 +8
US 3,586 3,326 +8 +1
Japan 1,139 671 +70 +40
Diagnostics Division 2,361 2,287 +3 +8
Roche Group 11,577 10,855 +7 +8
2. Quarterly local sales growth by Division in 2008 and 2009
Q2 2008 Q3 2008 Q4 2008 Q1 2009
vs. Q2 2007 vs. Q3 2007 vs. Q4 2007 vs. Q1 2008
Pharmaceuticals Division +5 +8 +5 +8
Europe/Rest of World +9 +7 +10 +8
US 0 +12 0 +1
Japan +2 -1 +5 +40
Diagnostics Division +13 +11 +9 +8
Roche Group +7 +9 +6 +8
3. Quarterly sales by Division in 2008 and 2009
CHF millions Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009
Pharmaceuticals Division 8,568 8,689 8,936 9,768 9,216
Europe/Rest of World 4,571 4,661 4,637 4,727 4,491
US 3,326 3,247 3,517 3,939 3,586
Japan 671 781 782 1,102 1,139
Diagnostics Division 2,287 2,460 2,365 2,544 2,361
Roche Group 10,855 11,149 11,301 12,312 11,577
---
4. Top 20 Pharmaceuticals Division product sales and local growth in YTD March 2009: US, Japan
and Europe/Rest of World
Total US Japan Europe/RoW
CHF % CHF % CHF % CHF %
m m m m
Avastin 1,485 30% 810 18% 82 147% 593 39%
MabThera/Rituxan 1,481 6% 769 6% 52 2% 660 6%
Herceptin 1,307 11% 390 0% 81 62% 836 13%
CellCept 517 7% 256 11% 11 15% 250 3%
Tamiflu 401 38% 15 -94% 250 1207% 136 487%
Pegasys 393 9% 101 17% 31 36% 261 5%
NeoRecormon/Epogin 378 -13% - - 115 -8% 263 -15%
Tarceva 320 13% 128 0% 15 51% 177 20%
Xeloda 296 8% 106 11% 15 53% 175 4%
Lucentis 279 21% 279 21% - - - -
Bonviva/Boniva 249 3% 137 -17% - - 112 40%
Xolair 152 13% 152 13% - - - -
Valcyte/Cymevene 131 7% 60 3% - - 71 11%
Activase/TNKase 126 45% 114 49% - - 12 19%
Pulmozyme 120 3% 75 14% - - 45 -9%
Nutropin 104 1% 101 1% - - 3 -12%
Xenical 103 -14% 8 -43% - - 95 -11%
Neutrogin 90 -22% - - 90 -22% - -
Rocephin 77 -15% 0 -97% 15 -3% 62 -13%
Madopar 68 0% - - 5 7% 63 0%
1 versus YTD March 2008
5. Top 20 Pharmaceuticals Division quarterly local product sales growth in 2008 and 2009
Q2 2008 Q3 2008 Q4 2008 Q1 2009
vs. Q2 2007 vs. Q3 2007 vs. Q4 2007 vs. Q1 2008
Avastin 38% 37% 36% 30%
MabThera/Rituxan 16% 15% 16% 6%
Herceptin 12% 14% 12% 11%
CellCept 16% 14% 11% 7%
Tamiflu -86% -56% -65% 38%
Pegasys 10% 12% 5% 9%
NeoRecormon/Epogin -14% -15% -8% -13%
Tarceva 27% 18% 19% 13%
Xeloda 14% 14% 12% 8%
Lucentis 2% 15% 19% 21%
Bonviva/Boniva 47% 26% 23% 3%
Xolair 7% 12% 13% 13%
Valcyte/Cymevene 10% 13% 9% 7%
Activase/TNKase -11% -2% 13% 45%
Pulmozyme 11% 6% 14% 3%
Nutropin -5% 1% -1% 1%
Xenical -21% -9% -11% -14%
Neutrogin 1% 0% -13% -22%
Rocephin -13% -16% -6% -15%
Madopar 9% 4% 3% 0%
6. Pharmaceuticals Division quarterly local product sales growth US in 2008 and 2009
Q2 2008 Q3 2008 Q4 2008 Q1 2009
vs. Q2 2007 vs. Q3 2007 vs. Q4 2007 vs. Q1 2008
Avastin 15% 18% 21% 18%
MabThera/Rituxan 13% 14% 15% 6%
Herceptin 3% 15% 3% 0%
CellCept 15% 20% 12% 11%
Tamiflu -87% 6% -83% -94%
Pegasys 5% 45% 9% 17%
NeoRecormon/Epogin - - - -
Tarceva 17% 9% 5% 0%
Xeloda 5% 9% 8% 11%
Lucentis 2% 15% 19% 21%
Bonviva/Boniva 39% 16% 12% -17%
Xolair 7% 12% 13% 13%
Valcyte/Cymevene 5% 7% 5% 3%
Activase/TNKase -12% -2% 13% 49%
Pulmozyme 14% 13% 24% 14%
Nutropin -4% 1% -1% 1%
Xenical -46% -33% -48% -43%
Neutrogin - - - -
Rocephin -85% - -89% -97%
Madopar - - - -
7. Pharmaceuticals Division quarterly local product sales growth Japan in 2008 and 2009
Q2 2008 Q3 2008 Q4 2008 Q1 2009
vs. Q2 2007 vs. Q3 2007 vs. Q4 2007 vs. Q1 2008
Avastin 1567% 442% 236% 147%
MabThera/Rituxan 11% 8% 9% 2%
Herceptin 29% 69% 73% 62%
CellCept 21% 15% 10% 15%
Tamiflu -78% -98% -2% 1207%
Pegasys 53% 49% 39% 36%
NeoRecormon/Epogin -29% -9% -16% -8%
Tarceva - - 699% 51%
Xeloda 73% 88% 81% 53%
Lucentis - - - -
Bonviva/Boniva - - - -
Xolair - - - -
Valcyte/Cymevene - - - -
Activase/TNKase - - - -
Pulmozyme - - - -
Nutropin - - - -
Xenical - - - -
Neutrogin 1% 0% -13% -22%
Rocephin -2% -1% 5% -3%
Madopar 5% 6% 0% 7%
8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World in 2008 and
2009
Q2 2008 Q3 2008 Q4 2008 Q1 2009
vs. Q2 2007 vs. Q3 2007 vs. Q4 2007 vs. Q1 2008
Avastin 78% 67% 52% 39%
MabThera/Rituxan 21% 17% 18% 6%
Herceptin 15% 11% 13% 13%
CellCept 16% 9% 9% 3%
Tamiflu -83% -93% 6% 487%
Pegasys 9% 1% 1% 5%
NeoRecormon/Epogin -7% -17% -4% -15%
Tarceva 28% 17% 24% 20%
Xeloda 18% 14% 12% 4%
Lucentis - - - -
Bonviva/Boniva 61% 45% 47% 40%
Xolair - - - -
Valcyte/Cymevene 16% 19% 14% 11%
Activase/TNKase 1% 1% 11% 19%
Pulmozyme 8% -3% 2% -9%
Nutropin -12% -10% -2% -12%
Xenical -17% -6% -7% -11%
Neutrogin - - - -
Rocephin -9% -13% -6% -13%
Madopar 9% 4% 4% 0%
9. Top 20 Pharmaceuticals Division quarterly product sales in 2008 and 2009
CHF millions
Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009
Avastin 1,131 1,220 1,351 1,505 1,485
MabThera/Rituxan 1,407 1,460 1,472 1,584 1,481
Herceptin 1,225 1,249 1,295 1,323 1,307
CellCept 487 523 513 576 517
Tamiflu 278 49 101 181 401
Pegasys 369 416 405 445 393
NeoRecormon/Epogin 442 450 427 455 378
Tarceva 286 301 298 330 320
Xeloda 281 292 307 331 296
Lucentis 215 225 246 274 279
Bonviva/Boniva 241 266 268 333 249
Xolair 125 134 145 156 152
Valcyte/Cymevene 125 136 143 149 131
Activase/TNKase 83 81 81 97 126
Pulmozyme 117 120 120 139 120
Nutropin 97 98 106 112 104
Xenical 136 128 126 112 103
Neutrogin 95 97 98 114 90
Rocephin 91 85 76 92 77
Madopar 74 80 77 80 68
10. Pharmaceuticals Division quarterly product sales in US in 2008 and 2009
CHF millions
Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009
Avastin 642 671 754 841 810
MabThera/Rituxan 675 706 732 817 769
Herceptin 363 349 394 390 390
CellCept 215 243 247 321 256
Tamiflu 234 30 96 70 15
Pegasys 81 95 99 120 101
NeoRecormon/Epogin - - - - -
Tarceva 119 123 117 136 128
Xeloda 89 97 111 131 106
Lucentis 215 225 246 274 279
Bonviva/Boniva 153 159 155 208 137
Xolair 125 134 145 156 152
Valcyte/Cymevene 54 62 66 76 60
Activase/TNKase 71 71 70 86 114
Pulmozyme 61 65 69 83 75
Nutropin 94 94 104 109 101
Xenical 14 12 9 8 8
Neutrogin - - - - -
Rocephin 3 1 0 1 0
Madopar - - - - -
11. Pharmaceuticals Division quarterly product sales in Japan in 2008 and 2009
CHF millions
Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009
Avastin 28 43 57 82 82
MabThera/Rituxan 43 52 51 68 52
Herceptin 42 56 64 87 81
CellCept 8 11 9 13 11
Tamiflu 16 0 1 71 250
Pegasys 19 22 26 35 31
NeoRecormon/Epogin 103 114 111 142 115
Tarceva 8 12 11 16 15
Xeloda 8 12 13 17 15
Lucentis - - - - -
Bonviva/Boniva - - - - -
Xolair - - - - -
Valcyte/Cymevene - - - - -
Activase/TNKase - - - - -
Pulmozyme - - - - -
Nutropin - - - - -
Xenical - - - - -
Neutrogin 95 97 98 114 90
Rocephin 13 15 14 19 15
Madopar 4 5 5 6 5
12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World in 2008 and 2009
CHF millions
Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009
Avastin 461 506 540 582 593
MabThera/Rituxan 689 702 689 699 660
Herceptin 820 844 837 846 836
CellCept 264 269 257 242 250
Tamiflu 28 19 4 40 136
Pegasys 269 299 280 290 261
NeoRecormon/Epogin 339 336 316 313 263
Tarceva 159 166 170 178 177
Xeloda 184 183 183 183 175
Lucentis - - - - -
Bonviva/Boniva 88 107 113 125 112
Xolair - - - - -
Valcyte/Cymevene 71 74 77 73 71
Activase/TNKase 12 10 11 11 12
Pulmozyme 56 55 51 56 45
Nutropin 3 4 2 3 3
Xenical 122 116 117 104 95
Neutrogin - - - - -
Rocephin 75 69 62 72 62
Madopar 70 75 72 74 63
|
|
 |
Dit is een bericht uit het Nieuwsbank persberichtenarchief. Gegevens in
dit bericht kunnen verouderd zijn. Overname is toegestaan onder
voorwaarden.
Eventueel in dit bericht vermelde (e-mail) adressen en telefoonnummers
zijn uitsluitend bedoeld voor journalisten.
Terug naar boven
|
|
